163 related articles for article (PubMed ID: 33123471)
21. Combination of tumor markers predicts progression and pathological response in patients with locally advanced gastric cancer after neoadjuvant chemotherapy treatment.
Liu Z; Wang Y; Shan F; Ying X; Zhang Y; Li S; Jia Y; Miao R; Xue K; Li Z; Li Z; Ji J
BMC Gastroenterol; 2021 Jul; 21(1):283. PubMed ID: 34246249
[TBL] [Abstract][Full Text] [Related]
22. Decrease in Neutrophil-to-Lymphocyte Ratio during Neoadjuvant Chemotherapy as a Predictive and Prognostic Marker in Advanced Ovarian Cancer.
Sanna E; Tanca L; Cherchi C; Gramignano G; Oppi S; Chiai MG; Macciò A; Madeddu C
Diagnostics (Basel); 2021 Jul; 11(7):. PubMed ID: 34359381
[TBL] [Abstract][Full Text] [Related]
23. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Vallius T; Peter A; Auranen A; Carpén O; Kemppainen J; Matomäki J; Oksa S; Roering P; Seppänen M; Grénman S; Hynninen J
Gynecol Oncol; 2016 Jan; 140(1):29-35. PubMed ID: 26515076
[TBL] [Abstract][Full Text] [Related]
24. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer.
Rouzier R; Pusztai L; Garbay JR; Delaloge S; Hunt KK; Hortobagyi GN; Berry D; Kuerer HM
Cancer; 2006 Oct; 107(7):1459-66. PubMed ID: 16948128
[TBL] [Abstract][Full Text] [Related]
25. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
[TBL] [Abstract][Full Text] [Related]
26. Clinical value of serum tumor markers in assessing the efficacy of neoadjuvant chemotherapy in advanced ovarian cancer: single-center prospective clinical study.
Huang J; Du D; Chen H; Luo D; Wang Q; Li C; Li Y; Yu Y
Front Oncol; 2024; 14():1399502. PubMed ID: 38863620
[TBL] [Abstract][Full Text] [Related]
27. Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease.
Santoro A; Angelico G; Piermattei A; Inzani F; Valente M; Arciuolo D; Spadola S; Mulè A; Zorzato P; Fagotti A; Scambia G; Zannoni GF
Front Oncol; 2019; 9():778. PubMed ID: 31482065
[No Abstract] [Full Text] [Related]
28. Elastography, a sensitive tool for the evaluation of neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma.
Xie M; Zhang X; Jia Z; Ren Y; Wang W
Oncol Lett; 2014 Oct; 8(4):1652-1656. PubMed ID: 25202385
[TBL] [Abstract][Full Text] [Related]
29. Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results.
Böhm S; Le N; Lockley M; Brockbank E; Faruqi A; Said I; Jeyarajah A; Wuntakal R; Gilks B; Singh N
Int J Gynecol Cancer; 2019 Feb; 29(2):353-356. PubMed ID: 30683759
[TBL] [Abstract][Full Text] [Related]
30. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
31. Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.
Rundo L; Beer L; Escudero Sanchez L; Crispin-Ortuzar M; Reinius M; McCague C; Sahin H; Bura V; Pintican R; Zerunian M; Ursprung S; Allajbeu I; Addley H; Martin-Gonzalez P; Buddenkotte T; Singh N; Sahdev A; Funingana IG; Jimenez-Linan M; Markowetz F; Brenton JD; Sala E; Woitek R
Front Oncol; 2022; 12():868265. PubMed ID: 35785153
[TBL] [Abstract][Full Text] [Related]
32. Advanced-Stage Nasopharyngeal Carcinoma: Restaging System after Neoadjuvant Chemotherapy on the Basis of MR Imaging Determines Survival.
Liu LT; Chen QY; Tang LQ; Zhang L; Guo SS; Xie CM; Liu XW; Guo L; Mo HY; Chen MY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Radiology; 2017 Jan; 282(1):171-181. PubMed ID: 27479804
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.
Petrillo M; Paris I; Vizzielli G; Amadio G; Cosentino F; Salutari V; Scambia G; Fagotti A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S952-8. PubMed ID: 26036187
[TBL] [Abstract][Full Text] [Related]
34.
Vallius T; Hynninen J; Kemppainen J; Alves V; Auranen K; Matomäki J; Oksa S; Virtanen J; Grénman S; Auranen A; Seppänen M
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1224-1232. PubMed ID: 29476227
[TBL] [Abstract][Full Text] [Related]
35. [Risk factor analysis on anastomotic leakage after laparoscopic surgery in rectal cancer patient with neoadjuvant therapy and establishment of a nomogram prediction model].
Jiang W; Feng MY; Dong XY; Dong SM; Zheng JX; Liu XM; Liu WJ; Yan J
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Aug; 22(8):748-754. PubMed ID: 31422613
[No Abstract] [Full Text] [Related]
36. Effect of increased number of neoadjuvant chemotherapy cycles on tumor resectability and pathologic response in advanced stage epithelial ovarian cancer.
Akilli H; Rahatli S; Tohma YA; Karakas LA; Altundag O; Ayhan A
J BUON; 2018 Dec; 23(7):111-115. PubMed ID: 30722119
[TBL] [Abstract][Full Text] [Related]
37. Machine Learning-Based Radiomics Nomogram Using Magnetic Resonance Images for Prediction of Neoadjuvant Chemotherapy Efficacy in Breast Cancer Patients.
Chen S; Shu Z; Li Y; Chen B; Tang L; Mo W; Shao G; Shao F
Front Oncol; 2020; 10():1410. PubMed ID: 32923392
[No Abstract] [Full Text] [Related]
38. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
[TBL] [Abstract][Full Text] [Related]
39. A Nomogram to Predict the Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Laboratory Indicators.
Zhang F; Huang M; Zhou H; Chen K; Jin J; Wu Y; Ying L; Ding X; Su D; Zou D
Ann Surg Oncol; 2019 Nov; 26(12):3912-3919. PubMed ID: 31359285
[TBL] [Abstract][Full Text] [Related]
40. The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer.
Plotti F; Scaletta G; Capriglione S; Montera R; Luvero D; Lopez S; Gatti A; De Cicco Nardone C; Terranova C; Angioli R
Int J Gynecol Cancer; 2017 May; 27(4):696-702. PubMed ID: 28406844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
